Progenics advances prostrate cancer treatment to phase 2 after FDA discussions

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

Tracon Pharmaceuticals shares slide 45% premarket after it ends trial of cancer treatment

Tracon Pharmaceuticals Inc. shares slid 45% in premarket trade Friday, after the cmpany said it is terminating a late-stage trial of a cancer treatment at the recommendation of an independent committee. The company said its phase 3 tria.....»»

Category: topSource: marketwatchApr 12th, 2019

Immunogen"s stock loses nearly half its value after trial of cancer treatment fails to meet primary endpoint

Shares of Immunogen Inc. plummeted 48% toward a two-year low in premarket trade Friday, after the company said a phase 3 trial of its ovarian cancer treatment, m.....»»

Category: topSource: marketwatchMar 1st, 2019

Cover story: Immunotherapy advances treatment in various types of cancer

Like a gas and brake pedal in a car, two different aspects of immunotherapy work simultaneously to thwart various types of cancer......»»

Category: topSource: bizjournalsNov 30th, 2018

Merck"s Keytruda Improves Survival in Esophageal Cancer Study

Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer. Merck & Co., Inc. MRK annou.....»»

Category: dealsSource: nytNov 15th, 2018

Progenics Pharma"s Stock Down on Dismal Phase III Study Data

Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection. .....»»

Category: worldSource: nytSep 20th, 2018

CTI BioPharma says trial of treatment for non-Hodgkin lymphoma failed to meet main goals

CTI BioPharma Corp. said Monday a late-stage trial of a treatment for the blood cancer non-Hodgkin lymphoma failed to meet its main goals. The Phase III trial evaluating Pixuvri combined with rituximab in comparison to gemcitabine combin.....»»

Category: topSource: marketwatchJul 9th, 2018

Merck Moves Ahead With Late-Stage Trial Win

Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for the treatment of metastatic non-small cell lung cancer met its primary endpoint......»»

Category: blogSource: 247wallstApr 9th, 2018

Merck"s stock surges after positive Keytruda trial results

Shares of Merck & Co. Inc. surged 2.6% in premarket trade Monday, after the drug maker said its cancer treatment Keytruda met the primary endpoint of a phase 3 trial evaluating the Keytr.....»»

Category: topSource: marketwatchApr 9th, 2018

3 Cancer Treatment Stocks to Buy in April

These three cancer stocks have tremendous upside potential......»»

Category: topSource: foxnewsApr 20th, 2019

Anixa Biosciences" licensed Car-T cancer treatment tech granted USPTO patent

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 17th, 2019

Roche lifts 2019 outlook after first-quarter sales beat

Swiss drugmaker Roche raised its 2019 outlook after first-quarter sales rose 8 percent, beating analyst estimates on the strength of newer medicines including multiple sclerosis treatment Ocrevus and cancer immunotherapy Tecentriq......»»

Category: topSource: reutersApr 17th, 2019

J&J beats estimates on pharma strength, raises sales forecast

Johnson & Johnson beat quarterly profit estimates on Tuesday and raised its adjusted sales growth forecast for the year, driven by demand for its treatment for psoriasis and Crohn's disease and cancer drugs Darzalex and Imbruvica......»»

Category: topSource: reutersApr 16th, 2019

Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic .....»»

Category: dealsSource: nytApr 15th, 2019

Why Clovis Bladder Cancer Treatment Rucaparib Is in Big Trouble

Clovis Oncology may have thought that it could sneak an announcement by late on Friday, but its shares were definitely paying the price Monday morning......»»

Category: blogSource: 247wallstApr 15th, 2019

Clovis Oncology stock tumbles after company halts bladder-cancer-treatment trial: report

Clovis Oncology Inc. stock tumbled more than 14% in after-hours trading Friday after the compa.....»»

Category: topSource: marketwatchApr 12th, 2019

Tracon Pharma terminates late-stage trial of cancer treatment

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 12th, 2019

Incysus Therapeutics gets FDA approval for brain cancer treatment trial

Incysus Therapeutics gets FDA approval for brain cancer treatment trial.....»»

Category: topSource: bizjournalsApr 9th, 2019

High Hopes for This Neulasta Biosimiliar for Cancer Treatment

Coherus BioSciences shares jumped on Monday morning after the firm released updated sales for its first quarter......»»

Category: blogSource: 247wallstApr 8th, 2019

MSK to open Nassau outpatient cancer center

Memorial Sloan Kettering Cancer Center will open MSK Nassau, a 114,000-square-foot outpatient cancer treatment facility on Hempstead Turnpike in Uniondale, next Monday. The center neighbors Nassau... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkApr 7th, 2019

Why Novocure Stock Fell More Than 10% in March

Despite last month's pullback, shares of this medical device company that's aiming to revolutionize cancer treatment are up 126% over the last year......»»

Category: topSource: foxnewsApr 6th, 2019